608 A clinical study to test the efficacy of VB1953 in clindamycin non-responder acne patients with antibiotic-resistant P. acnes

Resistant Propionibacterium acne strains can limit the efficacy of currently-used antibiotics and is emerging as a clinical challenge. There is an urgent need for new drugs that are effective against these resistant strains to treat moderate to severe inflammatory acne. Here we tested the safety, tolerability, and efficacy of VB1953, a topical 2% gel, applied b.i.d. over 12 weeks in an open label, single arm study in patients with clindamycin non-respondent/resistant acne vulgaris. Inclusion criteria were (i) moderate to severe (IGA grade 3 or 4) acne, (ii) at least 20 inflammatory and at least 20 non-inflammatory lesions; (iii) non-responder to topical clindamycin despite use over one month or more in any combination within 6 months prior to inclusion, and (iv) validation of resistant strains using semi-quantitative RT-PCR to detect the mutation confering high-grade resistance to clindamycin in P.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Interventional Studies, Clinical and Patient Outcomes Research Source Type: research